Many patients using GLP-1 medications choose Sculptra to address facial volume loss
Their main side effects are usually nausea and vomiting. In TRIUMPH-2, up to 11.6 percent of participants using retatrutide stopped the drug before the end of the trial due to side effects, compared with 4.9 percent of the placebo group
Participants average age was 58 years
The art of tissue-specific and disease-specific dosing may emerge in the not-too-distant future: Rather than using the current pharmacologic doses of GLP-1s to soak receptors throughout the body, we may learn how to apply much more tailored brush strokes to effectively treat, say, dementia or rheumatoid arthritis
Abbass NJ, Nahlawi R, Shaia JK, Allan KC, Kaelber DC, Talcott KE, et al